{"url_path":"/sec/upb/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/2022626/0001193125-26-220584-index.html","accession_number":"0001193125-26-220584","cik":"0002022626","ticker":"UPB","issuer_name":"Upstream Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022626/0001193125-26-220584-index.html","primary_entity_key":"0002022626","primary_entity_name":"Upstream Bio, Inc."},"word_count":2262,"has_tables":true,"body_markdown":"10-Q\n\nQ1false0002022626--12-3111http://fasb.org/srt/2025#ChiefExecutiveOfficerMember00020226262024-12-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626us-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-3100020226262025-03-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2026-03-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:CommonStockMember2025-01-012025-03-310002022626us-gaap:AdditionalPaidInCapitalMember2026-03-310002022626srt:MaximumMember2025-01-012025-03-310002022626upb:MaruhoAgreementMember2021-10-012021-10-310002022626us-gaap:ComputerEquipmentMember2025-12-310002022626us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310002022626upb:CRSwNPIndicationMember2026-01-012026-03-310002022626us-gaap:CommonStockMember2026-03-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310002022626us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626us-gaap:RestrictedStockMember2026-01-012026-03-310002022626us-gaap:CorporateDebtSecuritiesMember2026-03-310002022626us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2026-03-310002022626upb:MaruhoAgreementMemberupb:MaruhoCoLtdMember2026-03-310002022626us-gaap:RetainedEarningsMember2025-12-310002022626us-gaap:RetainedEarningsMember2025-01-012025-03-310002022626upb:AsthmaIndicationMember2026-01-012026-03-310002022626upb:MaruhoAgreementMemberupb:MaruhoCoLtdMember2026-01-012026-03-310002022626upb:TwoThousandTwentyFourStockOptionAndIncentivePlanAndTwoThousandTwentyOneStockOptionAndGrantPlanMember2026-03-3100020226262025-01-012025-03-3100020226262025-01-012025-12-310002022626us-gaap:LeaseholdImprovementsMember2025-12-310002022626us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310002022626us-gaap:LeaseholdImprovementsMember2026-03-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310002022626us-gaap:RestrictedStockUnitsRSUMember2025-12-310002022626us-gaap:EmployeeStockOptionMember2026-01-012026-03-310002022626us-gaap:RetainedEarningsMember2024-12-310002022626us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-310002022626us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310002022626upb:LonzaLicenseAgreementMember2026-01-012026-03-310002022626us-gaap:RetainedEarningsMember2026-01-012026-03-310002022626upb:COPDIndicationMember2025-01-012025-03-310002022626us-gaap:ComputerEquipmentMember2026-03-310002022626us-gaap:RestrictedStockMember2025-01-012025-03-310002022626upb:TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024-08-190002022626us-gaap:IPOMember2026-01-012026-03-310002022626us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626upb:MaruhoAgreementMemberupb:MaruhoCoLtdMember2025-01-012025-03-310002022626upb:TwoThousandTwentyFourStockOptionAndIncentivePlanMember2024-08-190002022626us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310002022626us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310002022626us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:EquipmentMember2025-12-310002022626us-gaap:RestrictedStockUnitsRSUMember2026-03-310002022626upb:TwoThousandTwentyFourEmployeeStockPurchasePlanMember2026-01-010002022626us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626us-gaap:CorporateDebtSecuritiesMember2025-12-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310002022626us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310002022626upb:TwoThousandTwentyFourStockOptionAndIncentivePlanMember2026-01-012026-03-3100020226262026-01-012026-03-310002022626us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310002022626upb:LonzaLicenseAgreementMember2021-10-012021-10-310002022626us-gaap:USTreasurySecuritiesMember2026-03-310002022626us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626upb:AsthmaIndicationMember2025-01-012025-03-310002022626us-gaap:AdditionalPaidInCapitalMember2024-12-310002022626us-gaap:OfficeEquipmentMember2025-12-310002022626us-gaap:RetainedEarningsMember2026-03-310002022626upb:MaruhoAgreementMemberupb:MaruhoCoLtdMember2025-12-3100020226262026-03-310002022626us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-12-310002022626us-gaap:CommonStockMember2025-12-310002022626upb:TwoThousandTwentyFourEmployeeStockPurchasePlanMember2026-01-012026-03-310002022626us-gaap:AdditionalPaidInCapitalMember2025-03-310002022626us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:USTreasurySecuritiesMember2025-12-3100020226262025-12-310002022626us-gaap:RetainedEarningsMember2025-03-310002022626us-gaap:OfficeEquipmentMember2026-03-310002022626upb:TwoThousandTwentyFourStockOptionAndIncentivePlanMember2026-03-310002022626upb:LonzaLicenseAgreementMember2025-01-012025-03-310002022626upb:COPDIndicationMember2026-01-012026-03-310002022626us-gaap:CommonStockMember2024-12-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002022626srt:MaximumMember2026-01-012026-03-310002022626us-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626upb:CRSwNPIndicationMember2025-01-012025-03-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310002022626us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002022626us-gaap:CommonStockMember2026-01-012026-03-310002022626us-gaap:EmployeeStockOptionMember2025-01-012025-03-310002022626us-gaap:CommonStockMember2025-03-310002022626us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-3100020226262026-05-070002022626upb:TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024-08-192024-08-190002022626us-gaap:EquipmentMember2026-03-310002022626us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310002022626us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626upb:TwoThousandTwentyFourStockOptionAndIncentivePlanMember2026-01-010002022626us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002022626us-gaap:AdditionalPaidInCapitalMember2025-12-310002022626us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31upb:Segmentxbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD\n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n \n\n \n\nFORM 10-Q\n\n \n\n \n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from _________________ to _________________\n\nCommission File Number: 001-42366\n\n \n\n \n\nUPSTREAM BIO, INC.\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n \n\nDelaware\n\n38-4187694\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\nIdentification No.)\n\n890 Winter Street, Suite 200\n\nWaltham, MA\n\n02451\n\n(Address of principal executive offices)\n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (781) 208-2466\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\n\nSymbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon Stock, par value $0.001 per share\n\n \n\nUPB\n\n \n\nThe Nasdaq Global Select Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n \n\n☐\n\nAccelerated filer\n\n \n\n☐\n\nNon-accelerated filer\n\n \n\n☒\n\nSmaller reporting company\n\n \n\n☒\n\n \n\n \n\n \n\n \n\nEmerging growth company\n\n \n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nAs of May 11, 2026, the registrant had 54,419,986 shares of common stock, $0.001 par value per share, outstanding.\n\n \n\nSpecial Note Regarding Forward-Looking Statements\n\nThis Quarterly Report on Form 10-Q (“Quarterly Report”) contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:\n\n•\nthe initiation, timing, progress, and results of our planned and future clinical trials for verekitug, for the treatment of severe asthma, chronic rhinosinusitis with nasal polyps (“CRSwNP”) and chronic obstructive pulmonary disease (“COPD”);\n\n•\nour ability to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties in current or future clinical trials;\n\n•\nour ability to demonstrate that verekitug and any potential future product candidates are safe and effective for their proposed indications and our expectations around their beneficial characteristics and therapeutic effects;\n\n•\nour ability to advance verekitug and any potential future product candidates through applicable regulatory approval processes, including timing of Investigational New Drug (“IND”) applications and final U.S. Food and Drug Administration (“FDA”) approval of verekitug or any future product candidate;\n\n•\nour estimates of the number of patients that we will enroll and our ability to initiate, recruit and enroll patients in and conduct and successfully complete our clinical trials at the pace we project;\n\n•\nthe implementation of our business model and strategic plans;\n\n•\nour ability to rely on third-party manufacturers and successfully manufacture verekitug for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;\n\n•\nour ability to commercialize verekitug, if approved, and obtain favorable pricing and reimbursement;\n\n•\nthe size and growth potential of the markets for verekitug and our ability to serve those markets;\n\n•\nour ability to realize the benefits of collaborations for the development and commercialization of verekitug or any other potential future product candidates;\n\n•\nour ability to maintain, expand and protect our intellectual property;\n\n•\ndevelopments relating to our competitors and our industry;\n\n•\nexisting regulations and regulatory developments in the United States and other jurisdictions;\n\n•\ngeneral economic, industry, market conditions and geopolitical developments, including interest rates, capital market disruptions, changes in or disruptions of U.S. governmental agencies, new or increased tariffs and retaliatory tariffs, trade\n\ni\n\nprotection measures, economic sanctions and economic slowdowns or recessions, military conflicts, such as the ongoing conflicts between Russia and Ukraine, the U.S. and Iran, and in the Middle East, and inflationary pressures;\n\n•\nour ability to attract, hire, and retain our key personnel and additional qualified personnel;\n\n•\nour anticipated use of our existing cash, cash equivalents and short-term investments;\n\n•\nour estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and\n\n•\nother risks and uncertainties, including those listed under the caption “Risk Factors.”\n\nIn some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. These statements are only predictions. Investors should not rely on such forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from those implied or projected by forward-looking statements include, among other things, those listed under the section titled “Risk Factors” and elsewhere in this Quarterly Report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. Investors should read this Quarterly Report, the documents that we reference in this Quarterly Report and the other documents that we file with the Securities and Exchange Commission (“SEC”) with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.\n\nWhile we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. Investors should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.\n\nIn addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.\n\nii\n\nRisk Factors Summary\n\nOur business is subject to numerous risks and uncertainties, which include, but are not limited to, the following:\n\n•\nWe are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.\n\n•\nWe will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.\n\n•\nVerekitug is our only product candidate, and we are dependent on a third party having accurately generated, collected and reported data from certain preclinical studies that were previously conducted for verekitug.\n\n•\nIf we are unable to advance verekitug in clinical development for one or more of the indications that we are pursuing, obtain regulatory approval and ultimately commercialize verekitug, or experience significant delays in doing so, our business will be materially harmed.\n\n•\nThe successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain.\n\n•\nThe regulatory approval processes of the FDA, the European Medicines Agency, and the European Commission and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for verekitug or any other potential future product candidates, our business will be substantially harmed.\n\n•\nVerekitug represents a novel approach to the treatment of inflammatory diseases, which makes it difficult to predict its likelihood of success and the timing and cost of development and obtaining regulatory approval.\n\n•\nIf our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize verekitug or any other potential future product candidates.\n\n•\nWe may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of verekitug or any other potential future product candidates, which could prevent us from achieving our projected development and commercialization goals in the timeframes we announce and expect, and harm our business and results of operations. Many of the factors that cause or lead to a delay in the initiation or completion of clinical trials may also lead to the denial of regulatory approval or limit market acceptance of verekitug or any other potential future product candidates.\n\n•\nVerekitug or any other potential future product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.\n\n•\nEven if verekitug or any other potential future product candidates receive regulatory approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.\n\n•\nCompetitive products may reduce or eliminate the commercial opportunity for verekitug or any other potential future product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize verekitug or any other potential future product candidates may be adversely affected. Our competitors may have significantly greater financial resources and expertise such that they may be more successful than us in obtaining regulatory approval and achieving widespread market acceptance.\n\niii\n\n•\nWe expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.\n\n•\nOur ability to develop verekitug or any other potential future product candidates and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel.\n\n•\nWe currently rely, and plan to rely in the future, on third parties to conduct and support our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize verekitug or any other potential future product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed.\n\n•\nOur use of third parties to manufacture verekitug or any other potential future product candidates may increase the risk that we will not have sufficient quantities of verekitug or any other potential future product candidates, raw materials, active pharmaceutical ingredients or drug products when needed or at an acceptable cost.\n\n•\nOur success is largely based upon our intellectual property and proprietary technologies, and we may be unable to protect and/or enforce our intellectual property.\n\nThe summary risk factors described above should be read together with the text of the full risk factors in the section titled “Risk Factors” and the other information set forth in this Quarterly Report, as well as in other documents that we file with the SEC. The risks summarized above or described in full elsewhere in this Quarterly Report are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.\n\niv\n\n \n\nTable of Contents\n\n \n\n \n\n \n\nPage\n\n \n\n \n\n \n\nPART I.\n\n[FINANCIAL INFORMATION](#part_i_financial_information)\n\n1"}